Listening to PYC's Q2 Investor update, in particular RP11, the patient who self reported an improvement in regard to perimetry vision did so 4 weeks after their 30mg dose in Cohort #3. Subsequent testing at 8 weeks confirmed this improvement by comparing the delta of the treated eye and the untreated eye.
In itself this is VERY EXCITING, and has prompted PYC to stratify patient selection criteria to focus on earlier stage RP11 patients for Cohort #4 (SAD), and also MAD study for RP11, (which is next in line).
If we see the same results replicated again in cohort #4, then that will give us, in total, four patients reporting visual improvement at a very early stage which would greatly enhance the conviction that PYC will ultimately be successful with their registrational study for RP11. Further confirmation via MAD study would elevate positive conviction even higher again. Bear in mind, cohort #4 dosing was completed about two weeks ago... the clock is ticking!
So in short, we can anticipate potential news in the fairly near future which may uplift sentiment for the success for RP11. Clearly the final mark sits with FDA approval, however in the interim, positive early results through RP11's natural history study could be immensely encouraging, IMO. Which begs the question, will the market also notice our pipeline in a more favourable light as well?
PYC Price at posting:
10.5¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)